



Republic of the Philippines  
DEPARTMENT OF HEALTH  
OFFICE OF THE SECRETARY  
**PURCHASE ORDER**

**Procurement of Sambong 250mg Tablet**

IB No. 2018-126

**SUPPLIER:** WESTFIELD PHARMACEUTICALS INC.  
**Address:** 831-A Eugenio Lopez St., cor. Edsa, Brgy. South Triangle, Quezon City  
**Telephone No.** Telefax No. (02) 441-4722  
**TIN** 003-939-361-000

**PO No.:** GOP-2018-05-058  
**Date:** MAY 28 2017  
**Mode of Procurement:** Competitive Bidding

**Sir/Madam:**

Please furnish this office of the following articles subject to the terms and conditions contained herein:

Place of Delivery:		Delivery Term:		Upon Delivery and Acceptance	
DOH Warehouse(s) or Service Provider(s) in Metro Manila		Mode of Payment:			
Date of Delivery:		Within Forty Five (45) calendar days upon receipt of approved Notice to Proceed (NTP)			
Item No.	Unit	Description	Quantity	Unit Cost	Amount
1	Treatment Pack	<b>Sambong 250mg Tablet</b>  <b>Name of Manufacturer:</b> Northfield Laboratories, Inc. <b>Country of Origin:</b> Philippines <b>Brand:</b> Renaleaf <b>Technical Specification:</b> <ul style="list-style-type: none"><li>• Sambong [Blumea Balsamifera, L. DC (Fam. Compositae)] oral 250 mg tablet</li><li>• It is commercially available in the Philippine market for the past two (2) years</li></ul> <b>Upon delivery the following shall be complied with:</b> <ul style="list-style-type: none"><li>• <b>Shelf Life:</b> Shelf life of at least <i>twenty-four (24) months</i> from the date of manufacture but not less than <i>eighteen (18) months</i> from the date of delivery.</li><li>• <b>Packaging Instructions:</b><ul style="list-style-type: none"><li>• Primary Packaging: Sixty (60) tablets per DOH Complete Treatment Pack</li><li>• Secondary Packaging: Standard packaging of the manufacturer including package insert or encryption/imprint inside the box as approved by PFDA.</li></ul></li><li>• <b>Labeling Instructions:</b> Standard labeling instruction as approved by Philippine Food and Drug Administration pursuant to Administrative Order No. 2016-0008.</li></ul> <b>In addition to the labelling requirement of FDA:</b> <ul style="list-style-type: none"><li>• On each <b>blister pack/foil strip and treatment pack</b>, the following should be legibly imprinted or stickered with non-removable or permanent sticker/label that is binding and with residue and tearing, if removed:  <b>Philippine Government Property-DOH</b> <b>Not for Sale</b></li><li>• On each <b>corrugated carton</b>, the following should be legibly imprinted or stickered with non-removable or permanent sticker/label that is binding and with residue and tearing, if removed:  <b>Philippine Government Property-DOH</b> <b>Not for Sale</b> <b>Manufacturing Date:</b> _____ <b>Expiration Date:</b> _____ <b>Batch/Lot No.:</b> _____</li></ul> <b>Product Recall/Replacement</b> The supplier must ensure the quality of drugs and if there will be problems in the quality, the supplier will recall and replace the drugs distributed in the regions and health centers based on the Guidelines on Product Recall, FDA Circular No. 2016-012.  <b>Other Requirements for Payment (for Drugs Medicines):</b> <ol style="list-style-type: none"><li>1. Within a period of thirty (30) days from receipt of delivery, a one hundred percent (100%) payment arrangement shall be made to the company upon receipt of satisfactory results of analysis from PFDA.</li><li>2. If, however, by thirty (30) days from receipt of delivery, PFDA cannot release the result of laboratory analysis, the company shall be paid fifty (50%) of the due amount. The remaining fifty percent (50%) balance is to be paid after obtaining a satisfactory PFDA report of analysis.</li><li>3. The supplier shall be charged of the laboratory testing fee for the test analysis of the delivered drugs and medicines. The payment shall be made directly by the supplier to the PFDA Cashier's Office. Otherwise, the Laboratory Test result will not be released to the Logistic Management Division (LMD) of the Department of Health.</li></ol> <b>The inspection and tests that will be conducted are:</b> <ol style="list-style-type: none"><li>1. Upon delivery, the Goods shall undergo preliminary physical inspection by the Inspection Team of the PROCURING ENTITY to ascertain the physical condition and acceptability of the Goods.</li><li>2. The supplier shall promptly replace the equivalent quantity of Goods taken as samples without cost to the PROCURING ENTITY.</li><li>3. Pending PFDA analysis, said products should not be distributed to end-users nor shall it be used until such time it is cleared by PFDA laboratory testing.</li><li>4. If PFDA inspection or results of laboratory analysis show major violations, the entire product line of the drug is temporarily suspended from accreditation, regardless of the batch or lot in question.</li><li>5. All health commodities with failed FDA test analysis shall immediately be pulled out by the suppliers from the DOH warehouse or from the warehouse of the DOH service provider within five (5) working days upon receipt of FDA test result from this Office.</li></ol> <p>Failure to comply within the prescribed time shall compel this Office to have the subject commodities pulled out by the third party logistics service provider of the DOH with the <b>hauling and freight fees chargeable against the concerned supplies</b>. In the observance of the above-mentioned timeline, please coordinate with the LMD-AS of the DOH.</p> <b>Purpose:</b> For the use of HEMB Note: Subject to the conditions stated in the Bidding Documents	50,000	88.280	4,414,000.00

Four Million Four Hundred Fourteen Thousand Philippine Pesos

4,414,000.00



Republic of the Philippines  
DEPARTMENT OF HEALTH  
OFFICE OF THE SECRETARY  
PURCHASE ORDER

Procurement of Sambong 250mg Tablet

IB No. 2018-126

GOR-2018-05-058

Supplier: **WESTFIELD PHARMACEUTICALS INC.**  
Address: 831-A Eugenio Lopez St., cor. Edsa, Brgy. South Triangle, Quezon City  
Telephone No. 003-939-361-000  
TIN 003-939-361-000

PO No.:  
Date:  
Mode of Procurement: **MAY 28 2018**  
Competitive Bidding

Sir/Madam:

Please furnish this office of the following articles subject to the terms and conditions contained herein:

Delivery Term:

Place of Delivery: DOH Warehouse(s) or Service Provider(s) in Metro Manila  
Date of Delivery: Within Forty Five (45) calendar days upon receipt of approved Notice to Proceed (NTP)

Mode of Payment:

Upon Delivery and Acceptance

**Liquidated Damages (Section 68 of the Revised IRR of RA9184):** All contracts executed in accordance with the Act and this IRR shall contain a provision on liquidated damages which shall be payable by the contractor in case of breach thereof. For the procurement of Goods, Infrastructure Projects and Consulting Services, the amount of the liquidated damages shall be at least equal to one-tenth of one percent (0.001) of the cost of the unperformed portion for every day of delay. Once the cumulative amount of liquidated damages reaches ten percent (10%) of the amount of the contract, the Procuring Entity may rescind or terminate the contract, without prejudice to other courses of action and remedies available under the circumstances.

**Warranty (Section 62 of the Revised IRR of RA 9184):** In order to assure that manufacturing defects shall be corrected by the supplier, a warranty security shall be required from the contract awardee for a minimum period of three (3) months, in the case of Expendable Supplies, or a minimum period of one (1) year, in the case of Non-expendable Supplies, after acceptance by the Procuring Entity of the delivered supplies. The obligation for warranty shall be covered by either retention money in an amount equivalent to at least one percent (1%) but not to exceed five percent (5%) of every progress payment, or a special bank guarantee equivalent to at least one percent (1%) but shall not exceed five percent (5%) of the total contract price. The said amounts shall only be released after the lapse of the warranty period, or, in the case of Expendable Supplies, after consumption thereof. Provided, however, that the supplies delivered are free from patent and latent defects and all the conditions imposed under the contract have been fully met.

By Authority of the Secretary of Health:

Conforme: *[Signature]*  
*Eugenia C. Balboa*  
Signature Over Printed Name of Supplier  
7-24-18

*[Signature]*  
**GLORIA J. BALBOA/MD, MHA, MPH, CEO VI, CESO III**  
Director IV  
Health Emergency Management Bureau

Date

ORS/BURS No.: **02-101101-2018-05-03794**

Date of the ORS/BURS: **12-29-18**

Amount: **P 4,414,000.00**

Fund Cluster: \_\_\_\_\_  
Funds Available: \_\_\_\_\_

**LORICA C. RABAGO** Building 1, San Lazaro Compound, Rizal Avenue, Sta. Cruz, 1003 Manila • Trunk Line 651-7800 local 1108, 1111, 1112, 1113  
Direct Line 711-9502; 711-9913 Fax: 743-1829 • URL: <http://www.doh.gov.ph> e-mail: [ldanque@doh.gov.ph](mailto:ldanque@doh.gov.ph)  
**DIG ACCOUNTING DIVISION**

PS / COBAC

APPROVED PO / CONTRACT

Received by: *[Signature]*

Date: **JUL 24 2018**

PS / COBAC

RELEASED: PO / CONTRACT

by: *[Signature]*

Date: **JUL 24 2018**